Lindsey Dohse, MD
Dermatopathology · Chillicothe, OHNPI 1073772810
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.8% of the total across 479 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AbbVie at 27.6% of the total. Reporting peaked in 2024 at $1,744 and has fallen 91.6% since, to $146 in 2025.
Across 479 payments — averaging $14.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$1K
- Novartis$634
- E.r. Squibb & Sons, L.L.C.$401
- UCB, Inc.$336
- Lilly USA, LLC$330
- plus $2K from 25 others
What the payments were for
- Food & beverage$6,65493%
- Education$5187%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 159 | $1,981 |
| Johnson & Johnson | 84 | $1,245 |
| Novartis | 50 | $634 |
| E.r. Squibb & Sons, L.L.C. | 20 | $401 |
| UCB, Inc. | 17 | $336 |
| Lilly USA, LLC | 20 | $330 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 18 | $259 |
| Sanofi | 14 | $256 |
| Bristol Myers Squibb | 11 | $228 |
| Regeneron Healthcare Solutions, Inc. | 10 | $200 |
| Amgen | 12 | $196 |
| Incyte Corporation | 9 | $169 |
| Pfizer | 9 | $161 |
| Boehringer Ingelheim | 5 | $126 |
| Dermavant Sciences, Inc. | 8 | $118 |
| Galderma Laboratories, L.p. | 6 | $79 |
| LEO Pharma Inc. | 4 | $64 |
| Sun Pharmaceutical Industries Inc. | 3 | $58 |
| Genentech USA, Inc. | 3 | $50 |
| Arcutis Biotherapeutics, Inc. | 3 | $44 |
| Biofrontera Inc. | 2 | $40 |
| Conmed Corporation | 1 | $39 |
| VYNE Pharmaceuticals Inc. | 2 | $27 |
| Merck | 2 | $27 |
| Botanix SB Inc | 1 | $25 |
| Almirall LLC | 1 | $18 |
| Fresenius Kabi USA, LLC | 1 | $15 |
| Blueprint Medicines Corporation | 1 | $15 |
| Mylan Institutional Inc. | 1 | $13 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $11 |
| Prugen, Inc. Pharmaceuticals | 1 | $5 |
How this compares
$7,171 in reported general payments places this provider in the 80th percentile of 25 dermatopathology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 98 | $366,547 |
| Humira(Cf) PenAdalimumab | 26 | $180,001 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 22 | $160,001 |
| OtezlaApremilast | 32 | $155,245 |
| Enbrel SureclickEtanercept | 14 | $108,107 |
| Enbrel MiniEtanercept | 14 | $101,956 |
| RinvoqUpadacitinib | 12 | $75,243 |
| AdbryTralokinumab-Ldrm | 15 | $57,743 |
| Tacrolimus | 32 | $5,795 |
| Fluorouracil | 64 | $4,927 |
| Acitretin | 15 | $2,994 |
| Mycophenolate Mofetil | 18 | $2,618 |
| Doxycycline Monohydrate | 75 | $2,085 |
| Mometasone Furoate | 112 | $2,062 |
| Doxycycline Hyclate | 74 | $1,512 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $196 | $155,24532 claims |
| AbbVieRinvoq | $1,981 | $75,24312 claims |
| LEO Pharma Inc.Adbry | $64 | $57,74315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 25 dermatopathology providers in Ohio.
Other dermatopathology in Chillicothe
- Melissa PiliangCleveland$123K
- Neera Agarwal AntalHudson$39K
- Adam HesselDublin$11K
- Katherine FeningMayfield Heights$10K
- Omar SalemSylvania$5K
- Joshua WeaverAkron$3K
- Janet WieselthierLyndhurst$3K
- Stephen SomachCleveland$3K
- Kimberly HollandsworthCleveland$2K
- Kyle WagamonWarren$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.